Comparing potential bispecific formats of trastuzumab and a humanized OKT3

Multispecific antibodies with varying designs continue to enter the clinic, with a recent report stating that 79 multispecific antibodies encompassing 25 different designs are now clinically available. At Absolute Antibody, we have produced more than 180 different engineered antibody formats. In this case study, we have taken two well-studied monoclonal antibodies and we have shown that not all bispecific formats are created equal.

This presentation covers how we systematically built and evaluated 17 bispecific designs, including a number of well-utilized formats. We found that Fc-containing formats and the placement of scFv can influence the expression dramatically, while interface stability for heterodimeric constructs is equally important.

Download the poster here.

View the video using the form below.

Absolute Antibody may use your contact information to send you information about the products and services from our Absolute Biotech family of brands. You can unsubscribe at any time by clicking the “unsubscribe” link included in every marketing email. For more information, please see our privacy policy here.